Richard Aspinall - Concepedia

Author

Richard Aspinall

Also Known As

Aspinall, Richard J, Aspinall, Richard J., Earl Williams, Nicholas Sharer, R Aspinall, R J ASPINALL, R J Aspinall, R. Aspinall, R. J Aspinall, R. J. Aspinall

125

Publications

3.4K

Citations

H-Index

Concepts

All Affiliations

Queen Alexandra Hospital University of Southampton National Institute for Health Research Portsmouth Hospitals NHS Trust Newcastle University

About

Richard Aspinall is an author at Queen Alexandra Hospital specializing in medicine, hepatology, and epidemiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	14	1.3K
2	Public Health	5	5	248
3	Health Sciences	1	1	306
4	Diabetes	1	1	306
5	Emergency Medicine	1	1	37

Richard Aspinall

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the WELCOME* study Eleonora Scorletti, Lokpal Bhatia, Keith McCormick, Hepatology PathologyEpa EnrichmentFatty Liver DiseaseObesityMetabolic Syndrome	2014	306
Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension Dhiraj Tripathi, Adrian J. Stanley, Peter Hayes, Gut HypertensionUrologyGrade SystemHepatologyPortal Hypertension	2020	296
Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease Eleonora Scorletti, Paul R. Afolabi, Elizabeth A. Miles, Gastroenterology DysbiosisMicrobiotaGut MicrobiologyLiver FatRandomized Trial	2020	208
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study Gideon M. Hirschfield, Mitchell L. Shiffman, Aliya Gulamhusein, Hepatology	2023	101
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials Jason Grebely, Gregory J. Dore, Stefan Zeuzem, Clinical Infectious Diseases PharmacotherapyAntiviral DrugViral HepatitisPan-genotypic RegimenClinical Trials	2016	91
Implementation of the Lancet Standing Commission on Liver Disease in the UK Roger Williams, Kathryn Ashton, Richard Aspinall, The Lancet Preventive MedicineHepatologyHealth PolicyLiver PhysiologyHepatitis	2015	88
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis Christopher L. Bowlus, Michael Galambos, Richard Aspinall, Journal of Hepatology HepatologyBiliary Tract52-Week StudyGastroenterologyPathology	2022	75
A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease Pui Lin Chong, David W Laight, Richard Aspinall, BMC Gastroenterology	2021	68
Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK Roger Williams, Graeme Alexander, Richard Aspinall, The Lancet Hepatic DisordersHepatologyHealth PolicyMedicineLiver Physiology	2018	63
The effects of cromakalim on ATP‐sensitive potassium channels in insulin‐secreting cells Mark J. Dunne, Richard Aspinall, Ole H. Petersen British Journal of Pharmacology	1990	53

Page 1